Intestinal Barrier Function and Liver Cirrhosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01081236|
Recruitment Status : Unknown
Verified December 2010 by Maastricht University Medical Center.
Recruitment status was: Recruiting
First Posted : March 5, 2010
Last Update Posted : December 16, 2010
Patients with liver cirrhosis have an increased risk to develop life-threatening complications such as spontaneous bacterial peritonitis (SBP). Impairment in the intestinal barrier, changes in numbers and composition of the intestinal microbiota and alterations in immune defenses have been suggested to be involved in liver cirrhosis and its complications. Dysfunction in the intestinal barrier for example results in the ongoing passage of toxic substances from the gastrointestinal tract that may damage the liver, leading to oxidative stress, inflammation and eventually liver cirrhosis. In addition, bacterial translocation is considered a key step in the development of spontaneous infections, mainly SBP, in patients with liver cirrhosis.
The investigators hypothesize that patients with decompensated liver cirrhosis have a more impaired intestinal epithelial barrier and altered intestinal microbiota than patients with compensated liver cirrhosis.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||62 participants|
|Official Title:||The Role of the Intestinal Barrier Function in Liver Cirrhosis|
|Study Start Date :||May 2010|
|Estimated Primary Completion Date :||May 2012|
|Estimated Study Completion Date :||May 2012|
|Compensated liver cirrhosis|
|Decompensated liver cirrhosis|
- The primary aim is to study differences in small and large intestinal permeability between patients with compensated and decompensated cirrhosis by means of a sugar permeability test [ Time Frame: 2 years ]
- To assess tight junction structure and proteins in biopsy specimens of small and large intestine [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01081236
|Contact: Kirsten Pijls, MDemail@example.com|
|Maastricht University Medical Center||Recruiting|
|Maastricht, Limburg, Netherlands|
|Contact: Kirsten Pijls, MD 0031433882157 firstname.lastname@example.org|
|Principal Investigator: Ad Masclee, MD PhD|
|Sub-Investigator: Kirsten Pijls, MD|
|Principal Investigator:||A Masclee, MD, PhD||Maastricht University Medical Center|